Overview

Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
0
Participant gender:
All
Summary
This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the treatment of sore throat due to a common cold.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis
Treatments:
Cetylpyridinium
Lidocaine
Criteria
Inclusion Criteria:

- Patients with sore throat due to an upper respiratory tract infection, with recent
onset (within 48 hours)

- Sore throat of at least moderate pain intensity

Exclusion Criteria:

- - History of hypersensitivity to any of the study drugs and listed excipients or to
drugs of similar chemical classes

- Evidence of mouth breathing or severe coughing

- Evidence of overt oropharyngeal bacterial or fungal infection or evidence of lower
respirator tract infection

- Severe renal, liver or cardiac impairment

- Severe lung disease